The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | COVID-19 risk factors in patients with hematologic malignancies
Lisa Hicks, MD, MSc, St. Michael’s Hospital, Toronto, ON, Canada, discusses the risk factors associated with hospitalization and mortality from COVID-19 in patients with hematologic malignancies. 1029 patients with a malignant diagnosis from the ASH Research Collaborative (RC) COVID-19 Registry for Hematology were included in the analysis, with the median age category being 50-59 years old. In the chosen cohort, 34% had acute leukemia/myelodysplastic syndrome (MDS), 25% had lymphoma, 20% had plasma cell dyscrasia, 11% had CLL, and 10% had a myeloproliferative neoplasm (MPN). Patients overall with blood cancer who male, over 60 years of age, a pre-COVID-19 prognosis of less than 6 months, and an ICR deferral were found to have an increased mortality risk from COVID-19. However, patients with a MPN or plasma cell dyscrasia were found to have a decreased hospitalization risk compared to other hematologic malignancies including leukemia and lymphoma. There was additionally no statistically significant link between receiving cancer treatment a year before COVID-19 diagnosis and increased risk of mortality as result of COVID-19. This press briefing was recorded at the American Society of Hematology (ASH) 2021 Annual Meeting and Exposition in Atlanta, GA.
